内科

目的探讨黄根片对胶质瘤U87-MG细胞增殖、迁移及侵袭的抑制作用及可能的机制。方法用不同生药浓度的黄根片组分溶液（0.125 mg/mL、0.25 mg/mL、0.5 mg/mL、1 mg/mL、2 mg/mL、4 mg/mL、8 mg/mL、16 mg/mL、32 mg/mL、64 mg/mL）干预U87-MG细胞，应用CCK-8实验计算干预24 h时药物的半数抑制浓度（IC50），以此确定后续实验分为对照组和黄根片低、中、高剂量组（生药浓度分别为3.25 mg/mL、6.5 mg/mL、13 mg/mL）。应用CCK-8、平板克隆形成实验检测各组U87-MG细胞的细胞活力和相对克隆形成率；应用Transwell迁移和侵袭实验检测各组U87-MG细胞的相对迁移、侵袭率；应用qRT-PCR法检测各组U87-MG细胞中miRNA-185-5p和分裂周期蛋白42（CDC42）mRNA的相对表达水平；应用蛋白质印迹法检测各组U87-MG细胞中CDC42、N-myc蛋白的相对表达水平。结果 U87-MG细胞存活率随黄根片给药浓度增加而逐渐降低，干预24 h时药物的IC50为13 mg（生药）/mL。黄根片低、中、高剂量组给药24 h、48 h、72 h、96 h后的细胞活力，给药7 d后的相对克隆形成率，给药48 h后的相对迁移和侵袭率均低于对照组（均P<0.05）。给药24 h后，黄根片低、中、高剂量组细胞中miRNA-185-5p的相对表达水平均高于对照组（均P<0.05）；给药24 h后，黄根片低、中剂量组中CDC42 mRNA的相对表达水平均低于对照组（均P<0.05）；给药24 h后，黄根片低、中、高剂量组中CDC42、N-myc蛋白的相对表达水平均低于对照组。结论黄根片能够抑制U87-MG人脑胶质瘤细胞的增殖、迁移和侵袭能力，从而发挥抗胶质瘤的作用。其机制可能与促进miRNA-185-5p的表达，进而抑制CDC42的表达有关。

Objective To explore the inhibitory effects of Huanggen Tablets on the proliferation, migration, and invasion of glioma U87-MG cells and the possible mechanisms. Methods U87-MG cells were intervened with Huanggen Tablets components solutions at different crude drug concentrations (0.125 mg/mL, 0.25 mg/mL, 0.5 mg/mL, 1 mg/mL, 2 mg/mL, 4 mg/mL, 8 mg/mL, 16 mg/mL, 32 mg/mL, 64 mg/mL). The 50% inhibitory concentration (IC50) of the drug at 24 hours after the intervention was calculated according to the results of the CCK-8 assay, based on which the subsequent experiment was designed to set up a control group, as well as a low-dose Huanggen Tablets group, a medium-dose Huanggen Tablets group, and a high-dose Huanggen Tablets group (with crude Huanggen concentrations of 3.25 mg/mL, 6.5 mg/mL, and 13 mg/mL, respectively). The CCK8 assay and plate colony formation assay were used to detect the cell viability and relative cloning formation rate of U87-MG cells in each group. The Transwell migration and invasion assays were used to detect the relative migration and invasion rates of U87-MG cells in each group. The qRT-PCR method was used to detect the relative expression levels of miRNA-185-5p and cell division cycle 42 (CDC42) mRNA in U87-MG cells of each group. Western blotting was used to detect the relative expression levels of CDC42 and N-myc proteins in U87-MG cells of each group. Results With the increase of the administration concentration of Huanggen Tablets, the survival rate of U87-MG cells gradually decreased, and its IC50 was 13 mg/mL(crude drug) at 24 hours after the intervention. The low-, medium-, and high-dose Huanggen Tablets groups had lower cell viability after 24, 48, 72, and 96 hours of administration, decreased relative cloning formation rate after 7 days of administration, and reduced relative migration and invasion rates after 48 hours of administration, as compared with the control group (all P<0.05). After 24 hours of administration, the relative expression levels of miRNA-185-5p in the cells of the low-, medium-, and high-dose Huanggen Tablets groups were all higher than those in the control group (all P<0.05). After 24 hours of administration, the relative expression levels of CDC42 mRNA in the low- and medium-dose Huanggen Tablets groups were lower than that in the control group (all P<0.05). After 24 hours of administration, the relative expression levels of CDC42 and N-myc proteins in the low-, medium-, and high-dose Huanggen Tablets groups were all lower than those in the control group. Conclusion Huanggen Tablets can inhibit the proliferation, migration, and invasion abilities of human glioma U87-MG cells, thus exerting an anti-glioma effect. Its mechanism may be related to promoting the expression of miRNA-185-5p, which in turn inhibits the expression of CDC42.